🔗 Share this article

As the US undertakes unprecedented adjustments to its vaccination guidelines, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by expressing skepticism about coronavirus vaccinations in the global health crisis and has zeroed in on potential deaths following Covid vaccination in her recent time at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Vaccine Program

Agency leaders planned to reveal sweeping revisions to the pediatric vaccination calendar in December, aligning the US with the Danish vaccine program, according to reports – a substantial departure that would place the US out of alignment with a large portion of the global community with no evidence for public health gain. The planned update has been delayed until the new year.

In place of the top vaccines chief, Dr. Høeg is scheduled to speak at the event. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth person to run the division this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment might represent a tighter collaboration between the drug and vaccine branches as Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a greater focus upon reevaluating already-approved immunizations at the FDA.

Høeg has often pushed for halting some pediatric vaccine recommendations in the US in order to be more like the Danish model, a society with comprehensive healthcare and a citizenry approximately the size of Wisconsin’s.

In her initial comments, she has kept her attention on vaccination policy – traditionally the domain of Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Concerns Over Expertise

Dr. Høeg has no apparent track record in pharmaceutical research, approval processes or leadership, which has been standard for former heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and CBER since March.

“It seems she lacks to have the necessary background” for leading the drug-regulation department, said a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in running a large organization. She has no expertise in pharmaceutical oversight.”

Former commissioners of CBER would “understand laws and regulations and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that prior appointees who ran CBER have had.”

CDER has an vast portfolio at the FDA, Woodcock pointed out.

“Many people just zeroes in on the innovative therapies, but the generic drug division approves a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and so forth, and all of those must be looked after,” Dr. Woodcock noted. “The responsibility you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a major administrative element to the role, which manages in excess of 5,000 staff members. “It’s a huge administrative position, if you execute it properly,” the former official added.

Official Statement and Contentious Initiatives

When asked about concerns about Dr. Høeg's qualifications and whether this appointment represents greater collaboration among agency officials on immunizations, a representative said that the “concerns are based on inaccurate assumptions”.

“This background is consistent with the responsibilities of her position,” the representative stated, pointing to the period Høeg spent advising the FDA commissioner on “medication safety and approval science, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg inherits the commissioner’s new expedited review system, a controversial rapid medication authorization process that allegedly concerned her predecessors. “How are these therapies being chosen for this expedited pathway? Who is making the calls?” Howard asked. “There’s a lot of confidentiality going on at the regulatory body right now.”

Overall, he remarked, “the FDA seems to be moving towards laxer rules of most medications, except for vaccines.”

Established Track Record on Immunizations

Regarding vaccines, Høeg has a clearer, if problematic, history, some experts observe. She published a analysis using unverified crowd-sourced reports to determine the frequency of myocarditis following Covid vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccinations are more dangerous than they are.

Part of her “wish list” for the new federal leadership encompassed changing regulations for recently developed shots and discontinuing “optional” vaccines, she stated post-election on a audio program. At the FDA, Høeg has allegedly suggested barring teenage boys from getting COVID-19 vaccines.

“She’s an all-around dogmatist who starts off with her conclusions and reverse-engineers to accommodate the data in a very disingenuous, fraudulent manner,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with other contrarians, {like|